Mayo Clinic

抗衰老药物在临床前研究中减少COVID-19症状。

妙佑医疗国际(Mayo Clinic)的研究人员和明尼苏达大学的同事表明,COVID-19(2019冠状病毒病)加剧了体内衰老细胞的破坏性影响。在临床前研究中,妙佑医疗国际研发的抗衰老药物显著降低了老年实验鼠因COVID(冠状病毒病)感染引起的炎症、疾病和死亡率。该研究结果已发表在《科学》期刊中。

 

衰老细胞(在体内持续存在的受损或无功能性细胞)会导致各种老化和疾病,包括炎症和多种慢性疾病。基于妙佑医疗国际提出的衰老细胞“放大器/变阻器假设”,研究人员尝试发现COVID-19如何在老年人和慢性疾病患者中引发更高的死亡率。他们表明,人类衰老细胞会放大对严重急性呼吸道综合征(SARS)刺突蛋白的反应,而激发形成更多由衰老细胞引发的炎症和组织损伤的诱导因子。

 

研究人员还发现,使用明尼苏达大学研发的模型于感染病毒(包括与SARS-CoV-2相关的冠状病毒)的老年实验鼠,有表现出扩大反应性的衰老细胞增加、发炎症状,并且死亡率接近100%。当研究人员在感染之前或之后用抗衰老药物(选择性去除体内衰老细胞的药物)治疗类似的实验鼠时,结果恰恰相反。抗病毒抗体增加,而炎症和衰老细胞出现的迹象以及死亡率则显著减少,因此受感染的老年实验鼠的存活率更加接近年轻的实验鼠。

 

研究人员建议,减轻老年或慢性疾病患者衰老细胞的现有负担可能会提升他们的恢复力,并降低他们死于病毒感染(包括SARS-CoV-2)的风险。目前正在开展三项此类临床试验。

 

“尽管疫苗的使用在不断增加,抗衰老药物仍然可以帮助无法接种疫苗的患者,特别是对疗养院中患有合并症或免疫问题的老年患者,”Kogod Center on Aging主任James Kirkland医学博士和妙佑医疗国际本研究的资深作者Tamar Tchkonia博士共同说道。该研究表明,抗衰老药物还可能改善老年患者对疫苗的反应,同时帮助他们对抗细菌和其他病毒感染。

 

该研究得到了如下机构的支持:美国国立卫生研究院、康纳基金会、Robert J.和Theresa W. Ryan、Robert P.和Arlene R. Kogod、诺伯基金会、明尼苏达大学临床与转化科学研究所、衰老生物学医学发现团队,以及艾琳钻石基金会/美国老化研究联合会博士后转型10奖项。此外,该研究还获得了Fesler-Lampert老化研究主席奖和AFAR青年教员奖。

 

###

 

关于妙佑医疗国际(Mayo Clinic)

 

妙佑医疗国际是一所致力于创新并集临床实践、医学教育和科学研究为一体的非营利机构,以恻隐之心竭诚提供精湛医术和解决方案给需要治疗的每个人请访问妙佑医疗国际新闻网,取得更多妙佑医疗国际的新闻信息关于COVID-19的详情,包括妙佑医疗国际的冠状病毒分布图追踪工具含有的14天COVID-19趋势预报,请访问妙佑医疗国际COVID-19资源中心。

 

 

媒体联系: 

请联系妙佑医疗国际公共事务部:Bob Nellis。邮箱:[email protected] 



Filters close

Showing results

110 of 5857
Released: 22-Jun-2021 5:10 PM EDT
Tecnología de inteligencia artificial y ECG puede rápidamente descartar infección por COVID-19
Mayo Clinic

La inteligencia artificial puede ofrecer un manera de determinar con exactitud que una persona no está infectada con la COVID-19. Un estudio internacional y retrospectivo descubrió que la infección por SARS-CoV-2, el virus que causa la COVID-19, provoca sutiles cambios eléctricos en el corazón. Un electrocardiograma (ECG) mediado por inteligencia artificial detecta estos cambios y puede servir como una prueba rápida y confiable para descartar la infección por COVID-19.

Released: 22-Jun-2021 4:45 PM EDT
Penn Medicine to Use $1M from City of Philadelphia for Additional Community Vaccination Clinics
Perelman School of Medicine at the University of Pennsylvania

Penn Medicine will continue its collaboration with the West and Southwest Philadelphia communities to operate a series of COVID-19 vaccine clinics in partnership with community organizations, faith-based institutions, restaurants, barbershops, and even professional sports teams thanks to $1 million in funding from the City of Philadelphia, in partnership with PMHCC.

Released: 22-Jun-2021 12:30 PM EDT
Political Variables Carried More Weight Than Healthcare in Government Response to COVID-19
Binghamton University, State University of New York

Political institutions such as the timing of elections and presidentialism had a larger influence on COVID-19 strategies than the institutions organizing national healthcare, according to a research team led by a professor at Binghamton University, State University of New York.

22-Jun-2021 12:00 PM EDT
Study Testing How Well COVID-19 Vaccine Prevents Infection and Spread of SARS-CoV-2 Among University Students Now Expands to Include Young Adults Beyond the University Setting
Covid-19 Prevention Network (CoVPN)

The Prevent COVID U study, which launched in late March 2021 to evaluate SARS-CoV-2 infection and transmission among university students vaccinated with the Moderna COVID-19 Vaccine, has expanded beyond the university setting to enroll young adults ages 18 through 29 years and will now also include people in this age group who choose not to receive a vaccine.

Newswise: First Wave COVID-19 Data Underestimated Pandemic Infections
18-Jun-2021 8:30 AM EDT
First Wave COVID-19 Data Underestimated Pandemic Infections
American Institute of Physics (AIP)

Two COVID-19 pandemic curves emerged within many cities during the one-year period from March 2020 to March 2021. Oddly, the number of total daily infections reported during the first wave is much lower than that of the second, but the total number of daily deaths reported during the first wave is much higher than the second wave.

Newswise: PNNL AI Expert Harnesses Open-Source Data to Understand Human Behavior
Released: 22-Jun-2021 9:55 AM EDT
PNNL AI Expert Harnesses Open-Source Data to Understand Human Behavior
Pacific Northwest National Laboratory

PNNL researchers used natural language processing and deep learning techniques to reveal how and why different types of misinformation and disinformation spread across social platforms. Applied to COVID-19, the team found that misinformation intended to influence politics and incite fear spreads fastest.

Released: 22-Jun-2021 8:30 AM EDT
Engineering Nanobodies As Lifesavers When SARS-CoV-2 Variants Attack
Ohio State University

Scientists are pursuing a new strategy in the protracted fight against the SARS-CoV-2 virus by engineering nanobodies that can neutralize virus variants in two different ways.

Released: 21-Jun-2021 3:45 PM EDT
Rare Neurological Disorder Documented Following COVID-19 Vaccination
American Neurological Association (ANA)

In two separate articles in the Annals of Neurology, clinicians in India and England report cases of a rare neurological disorder called Guillain-Barré syndrome after individuals were vaccinated against COVID-19.

Newswise: New Analysis reveals link between birthdays and COVID-19 spread during the height of the pandemic
17-Jun-2021 12:10 PM EDT
New Analysis reveals link between birthdays and COVID-19 spread during the height of the pandemic
Harvard Medical School

Risk of SARS-CoV-2 infection increased 30 percent for households with a recent birthday in counties with high rates of COVID-19 Findings suggest informal social gatherings such as birthday parties played role in infection spread at the height of the coronavirus pandemic No birthday-bash infection jumps seen in areas with low rates of COVID-19 Households with children’s birthdays had greater risk of SARS-CoV-2 infection than with adult birthdays

Newswise: COVID-19 dual-antibody therapies effective against variants in animal study
Released: 21-Jun-2021 10:05 AM EDT
COVID-19 dual-antibody therapies effective against variants in animal study
Washington University in St. Louis

A study from Washington University School of Medicine in St. Louis suggests that many, but not all, COVID-19 therapies made from combinations of two antibodies are effective against a wide range of virus variants, and that combination therapies appear to prevent the emergence of drug resistance.


Showing results

110 of 5857

close
0.9806